Medikamentöse Behandlung des Lungenkarzinoms – Grundlagen und neue Säulen der Therapie

Kaum ein Feld entwickelt sich derzeit so dynamisch wie die Therapie des metastasierten Lungenkarzinoms. Die Ära der zielgerichteten Therapie wird erweitert durch die gerade begonnene Ära der Immuntherapie. Vielfältige Kombinationen von Immuntherapeutika, aber auch von Immuntherapie mit Chemotherapie, Strahlentherapie und zielgerichteter Therapie, sowie auch der in diesem Artikel nicht beleuchteten Vakzinierung sind vorstellbar und bereits jetzt in klinischen Studien. Eine sorgfältige Planung der Studien, die Erarbeitung von prädiktiven „Biomarkern“ sowie die Diskussion über relevante Endpunkte sind Voraussetzungen für die erfolgreiche Weiterentwicklung des Feldes und die Umsetzung in die klinische Praxis.

Hardly any other field has recently undergone such a dynamic development as the therapy for metastatic lung cancer. The scope of targeted therapy has now been expanded with the newly commenced era of immune therapy. Not only a multitude of combinations of immunotherapeutics but also of immune therapy with chemotherapy, radiotherapy and targeted therapy are imaginable and in part already undergoing clinical trials, as well as those with vaccinations which will not be covered in this article. Careful planning of the trials, the elaboration of predictive “biomarkers” and comprehensive discussion of relevant endpoints are prerequisites for the successful continuing development of the field and its implementation in clinical routine.

Key words

Lung cancer - targeted therapy - immune therapy - chemotherapy - biomarkers

• Literatur

• 1 Barlesi F, Blons H, Beau-Faller M et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol abstr 8000 2013; 31 (Suppl. 01)
• 2 Schuette W, Schirmacher P, Eberhardt WE et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Prev 2015; 24: 1254-1261
• 3 Halbfass V, Prenzel R, Scriba D et al. Incidence of EGFR, KRAS, BAF, ALK and p53 alterations in a cohort of 159 consecutively tested patients from 1 DKG cervified lung cancer center and correlation with clinical characteristics. Onkologie 2013; 36: 251-251
• 4 Sebastian M, Niederle N, Thomas M et al. Molecular genetic tests in advanced non-small cell lung cancer: practical relevance. Dtsch Med Wochenschr 2014; 139: 2096-2100
• 5 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009; 361: 947-957
• 6 Sequist LV, Yang JC, Aymamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334
• 7 Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-222
• 8 Park K, Tan EH Zhang et al. Afatinib versus gefitinib as first-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations: LUX-Lung 7. ESMO ASIA 2015;
• 9 Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Nat Cancer Inst 2013; 105: 595-605
• 10 Yang JC, Swquist LV, Geater SL et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015; 16: 830-838
• 11 Oxnard GR, Arcila ME, Sima CS et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17: 1616-1622
• 12 Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247
• 13 Heuckmann JM, Rauh D, Thomas RK. Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. J Clin Oncol 2012; 30: 3417-3420
• 14 Jänne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. New Engl J Med 2015; 372: 1689-1699
• 15 Sequist LV, Soria JC, Goldman JW et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. New Engl J Med 2015; 372: 1700-1709
• 16 Park K et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). ASCO Meeting Abstracts 2015; 33 (Suppl. 15)
• 17 Mok T et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). ASCO Meeting Abstracts 2015; 33 (Suppl. 15)
• 18 Mok T, Wu Y, Nakagawa K et al. Gefitinib/chemotherapy vs. chemotherapy in epidermal growth factor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomised IMPRESS study. Program and abstracts of the European Society of Medical Oncology 2014 Congress; September 26–30, 2014; Madrid, Spain. Abstract LBA 2.
• 19 Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. New Engl J Med 2013; 368: 2385-2394
• 20 Solomon BJ, Mok T, Dim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med 2014; 371: 2167-2177
• 21 Ou SH, Jänne PA, Bartlett CH et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014; 25: 415-422
• 22 Shaw AT, Kim DW et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. New Engl J Med 2014; 370: 1189-1197
• 23 Gainor JF, Tan DS, De Pas T et al. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res 2015; 21: 2745-2752
• 24 Felip E et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2015; 33 (Suppl. 15)
• 25 Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. New Engl J Med 2014; 371: 1963-1971
• 26 Planchard D et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2015; 33 (Suppl. 15)
• 27 Drilon AE et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. ASCO Meeting Abstracts 2015; 33 (Suppl. 15)
• 28 Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31: 1997-2003
• 29 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New Engl J Med 2015; 373: 123-135
• 30 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small Cell Lung Cancer. New Engl J Med 2015; 373: 1627-1639
• 31 Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. New Engl J Med 2015; 372: 2018-2028
• 32 Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Dec 18 [Epub ahead of print] 2015;